8.07
+1.00%
Close of 9 Nov 2026, in CNY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Landfar Bio medicine Co
Its shares trade on Shenzhen under the ticker 000504.SZ. It has been listed since 8 December 1992. In the fiscal year to 31 December 2025, it reported revenue of CN¥415.9m and net income of CN¥28.8m. At that date it held total assets of CN¥991.7m and shareholders' equity of CN¥265.8m.
NanHua Bio-medicine Co., Ltd. engages in the manufacture and sale of pharmaceutical products. The company is headquartered in Changsha, Hunan. The Company’s biomedical business includes stem cell storage and technical services, stem cell treatment research, medical instrument purchasing & sales. The Company’s energy conservation & environmental protection business includes energy management company (EMC) contract energy management, build-transfer (BT), product sales, and sewage treatment. The firm is involved in other businesses related to aid and build project. The firm mainly conducts businesses within the domestic market.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 8 Dec 1992
- Employees
- 512
- Website
- nhbiogroup.com ↗
Leadership
Pay as last reported
- Mr. Bingxian ZhaoChairman of the Board, since 2002
- Ms. Caixia ZhaoVice Chairman of the Board, Secretary of the Board, since 2022
- Mr. Pengbin LinFinance Director, Deputy General Manager
- Mr. Changqiao YouGeneral Manager, Director
- Mr. Yong ChenDeputy General Manager, Secretary of the Board
- Mr. Liang SuDeputy General Manager, Secretary of the Board
- Mr. Ailong LiuDeputy General Manager
- Mr. Haiyi CaoDirector
- Mr. Yuan ChenDirector
- Mr. Xiaoping LuDirector, since 2011CN¥36,000
- Mr. Feng LinIndependent Director
- Ms. Liwen SheIndependent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Company has a long history with IPO in 1992
- Company employs 512 full-time employees
- Company operates in multiple business segments including biomedical and energy conservation
Weaknesses
- Company's business is primarily domestic with limited international presence
- Company's website is not provided with specific content details
- Company's business segments include energy conservation which may not align with core biotechnology focus
Opportunities
- Expansion into international markets could leverage existing domestic success
- Growth in stem cell technology and treatment research presents new market opportunities
- Potential for increased partnerships in biomedical and environmental sectors
Threats
- Competition from other biotechnology firms in domestic market
- Regulatory changes in healthcare and environmental sectors could impact operations
- Economic downturns may affect demand for non-essential medical services and environmental projects
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.